Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Riluzole
100%
Bevacizumab
100%
Metastatic Colorectal Cancer (mCRC)
100%
Phase I Trial
100%
MFOLFOX6
100%
Twice Daily
33%
Stable Disease
33%
5-fluorouracil (5-FU)
33%
FOLFIRINOX
33%
United States
16%
Amyotrophic Lateral Sclerosis
16%
Overall Survival
16%
Standard of Care
16%
Colorectal Cancer
16%
Cancer Mortality
16%
Synergize
16%
Cell Viability
16%
Partial Response
16%
Targeted Agents
16%
Glutamate Release
16%
Progressive Disease
16%
Duration of Response
16%
Once-daily
16%
Cancer Causes
16%
Disease Resistance
16%
New Treatment Options
16%
Clinical Activity
16%
Disease Control Rate
16%
Locally Advanced Disease
16%
Objective Response Rate
16%
Microsatellite Stable
16%
Colorectal Cancer Cell Lines
16%
Oral Medicine
16%
Well Tolerated
16%
95% Confidence Interval
16%
Median Progression-free Survival
16%
Medicine and Dentistry
Clinical Trial
100%
Bevacizumab
100%
Metastatic Colorectal Cancer
100%
Riluzole
100%
Diseases
83%
Fluorouracil
33%
FOLFOX
33%
Malignant Neoplasm
16%
Arm
16%
Progression Free Survival
16%
Overall Survival
16%
Cell Viability
16%
Progressive Disease
16%
Glutamic Acid
16%
Disease Resistance
16%
Colorectal Carcinoma
16%
Phase I Trials
16%
Amyotrophic Lateral Sclerosis
16%
Colorectal Cancer Cell Line
16%
Oral Medicine
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Bevacizumab
100%
Metastatic Colorectal Cancer
100%
Riluzole
100%
Diseases
100%
Fluorouracil
33%
Colorectal Carcinoma
33%
Malignant Neoplasm
16%
Progression Free Survival
16%
Overall Survival
16%
Preclinical Study
16%
Cell Viability
16%
Glutamic Acid
16%
Amyotrophic Lateral Sclerosis
16%
Disease Resistance
16%
Phase I Trials
16%